FDA urges drugmakers to add new label info on antidepressant risks

Share this article:
FDA urges drugmakers to add new label info on antidepressant risks New information concerning risks to newborns and migraine sufferers should be added to the labels of selective serotonin reuptake inhibitors (SSRIs) and certain selective serotonin /norepinephrine reuptake inhibitors (SNRIs), the FDA said. The agency warned that taking the antidepressants in combination with triptan migraine medications could result in the life-threatening condition known as serotonin syndrome. The agency also warned about a fatal lung condition in newborns whose mothers took SSRIs during pregnancy. SSRIs include GlaxoSmithKline’s Paxil, Eli Lilly’s Prozac, Pfizer’s Zoloft and Symbyax, Forest’s Celexa and Lexapro and Solvay Pharmaceutical’s Luvox. SNRIs cited by the FDA included Lilly’s Cymbalta and Wyeth’s Effexor.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.